Our Story

We founded MedAvante in 2002 to address a crisis in mental health clinical trials.

Pharma was facing unsustainable failure rates testing psychotropic drugs. Because outcomes in these studies are based on subjective assessments which can be influenced by biases and obscured by variability, developers of treatments for central nervous system (CNS) disorders were having increasing difficulty detecting the conclusive signal needed to prove efficacy, even with treatments already known to be effective.

As a result, pressure was mounting to move drug development investment away from mental health in spite of the large and growing unmet medical need. For us, this was personal: we’d seen individuals close to us devastated by the diseases for which new treatments were needed.

Studying this problem for nearly a year, we came to believe that there had to be a better way. We believed drug developers were not well served by conventional wisdom that said failed trials, soaring costs and untenable delays were unavoidable. And we believed those who said we wouldn’t be able to affect trial failure in a material way were overlooking the tremendous potential of combining scientific, clinical and technical skills to forge a new way of understanding the root causes of bias and variability.

The result was Central Ratings, an unconventional solution built on the novel idea of administering clinical outcome assessments remotely. Centralization effectively blinds raters to potentially prejudicial sources of bias and significantly reduces the number of raters needed for a study, improving standardization and minimizing variability.

As Central Ratings gained acceptance and grew into a global solution, in 2009 we developed a second groundbreaking methodology: replacing paper-based rating scales with real-time digital collection and management “in the cloud” of electronic source data – long before anyone ever heard the term “eSource.”

Our scientific, clinical and technical experience came together again in the Virgil eSource platform, which improves signal detection and data quality by providing any rater – from our own MedAvante cohort or at any study site, anywhere in the world – with real-time clinical guidance, auto-calculated scores and prompts for missing data and out-of-range errors. Virgil can improve clinical trials in any therapeutic area where it’s important to find a clear signal of treatment efficacy.

Virgil has been used by MedAvante Central Raters to administer and score hundreds of thousands of assessments globally and our eSource data has been accepted by both the FDA and the EMA in successful regulatory submissions; these are unique credentials that only MedAvante can claim.

We believe that continuing innovation in the collection, management and analysis of clinical trial data holds the key to unlocking new, more effective treatments. We will continue to build on the great strides we’ve made in signal detection, and we remain fully committed to smarter, faster clinical trials in all therapeutic areas that will bring better treatments to the people who need them most.

Our Vision

We strive for smarter,
faster clinical trials.

NJF2014logo_cmyk_orangeaward-red-herring-americas-100-CROPinc-500-500-logoEOY_Recipient12_EN-1024x255

Paul M Gilbert

Co-Founder & Chief Executive Officer

Paul Gilbert has 30 years of leadership, strategy, and innovation experience at best-practice organizations including Johnson & Johnson, Arm & Hammer, Booz Allen and Gillette. He has successfully scaled up companies in both consumer and business markets with an emphasis on innovating new markets.

One of three co-founders of MedAvante, Mr. Gilbert has led the building of a global team that now delivers signal detection services for clinical trials in more than 40 countries worldwide. His leadership focus has been on mobilizing exceptional talent, capital and resources to pioneer powerful methodological innovations to address the high rate of failed central nervous system (CNS) clinical trials, including remote Central Ratings and electronic source documents (eSource). He also ensures that MedAvante’s culture, organizational design, business model and strategy reinforce service excellence. Mr. Gilbert led MedAvante’s acquisition of $49 million in growth capital, including an initial $14 million round from 82 organizational leaders from Pharma, Wall Street and innovative growth company CEOs who continue to provide expertise and insights.

Prior to MedAvante, Mr. Gilbert was Vice President of Marketing and Strategy for Princeton eCom, which was awarded New Jersey Technology Council’s 2001 Technology Company of the Year, overseeing the development and execution of all marketing and strategy initiatives.

He has served most recently on the boards of Derma Sciences, a publicly traded tissue regeneration company, and the prestigious non-profit International Longevity Centre Global Alliance (acquired by Columbia University). He’s been invited to present on innovation multiple times at Princeton and Wharton and is a strategic advisor to young innovative companies. In 2012, Mr. Gilbert was awarded the Ernst & Young Lifesciences Entrepreneur of the Year.

Mr. Gilbert graduated magna cum laude from Bowdoin College where he was named a James Bowdoin Scholar, and received his MBA from Harvard University.

Steven Herne

Chief Commercial Officer

Steve Herne, an experienced sales and business development executive in both technology and services, joined MedAvante-Prophase as Chief Commercial Officer in July 2017 with overall responsibility for sales and marketing.

Prior to his appointment, he was Chief Commercial Officer, eHealth Solutions at Bioclinica, a provider of clinical trial management solutions. Previously, he served as Chief Commercial Officer at clinical trial data and technology company ERT, and Senior Vice President, Global Business Development at Icon Development Solutions. Earlier, he was a Vice President at Covance in the United Kingdom, and a Senior Director at MDS Pharma Services.

Herne began his career as a Senior Research Scientist for Inveresk Research before moving to a business development position at Quintiles and then returned to Inveresk as Senior Business Development Manager.

Steven Downing

Chief Financial Officer

Steve Downing has more than 25 years of experience in finance and business.

Before joining MedAvante, Mr. Downing served as Executive Director of Finance for the Client Support Center of Excellence for Covance. In that position, he led the planning and implementation of a finance reorganization process. Mr. Downing also lent support to responsibility, strategy, capital investment, expansion and financial training. In addition, he led a team responsible for the overall financial health of projects, including profitability, revenue recognition, cash flow, invoicing, and financial training for project managers and their teams.

His previous roles at Covance included Global Controller for the Clinical Development Services Business and Senior Financial Analyst for the Corporate office. Before joining Covance, Mr. Downing worked as a Senior Consolidations Analyst with IMO Industries and as an auditor with KPMG Peat Marwick LLP.

Mr. Downing has a BS in Accounting and Finance from Trenton State College, and is a Certified Public Accountant.

Peter Sorantin, PhD

Senior Vice President, Business Development & Communications

Dr. Sorantin has more than 15 years of experience in the biopharma and chemical industries. Before joining MedAvante, Dr. Sorantin worked in business development at SciQuest, establishing the key account program with international pharma companies and leading the company’s expansion into the European market.

Prior to SciQuest, Dr. Sorantin worked in business development at Molecular Simulations/Accelrys, where he expanded the company into formulation-related applications in pharmaceutical development and consumer care. He began his career at Siemens, leading the initiative to deliver new high-performance computational methods in predictive modeling to pharmaceutical companies and research institutions.

Dr. Sorantin holds a PhD in Physical Chemistry from the Vienna University of Technology in Austria, and has written a variety of scientific publications.

Angela Wilmer

Vice President, Regulatory and Quality Assurance

Since joining MedAvante in 2002, Angela Wilmer has developed provider networks and managed both the Rater Operations and Human Resources departments. She executed the company’s first feasibility study using videoconferencing. As Vice President of Regulatory and Quality Assurance since 2008 she has been responsible for evaluating activities of regulatory significance and ensuring that quality standards and regulatory requirements are implemented and maintained throughout the organization while leading audit teams in successful completion of more than 60 customer audits without a single significant finding. Widely recognized for her achievements in organizational leadership, Ms. Wilmer is often sought for advice and collaboration and asked to share her expertise with professionals worldwide through networking and consulting.

Before joining MedAvante, Ms. Wilmer worked for more than 20 years in health care where she developed expertise in regulation interpretation. At Horizon Blue Cross Blue Shield of New Jersey, she successfully developed and managed health care policies and administrative procedures to ensure compliance with regulatory agencies and other standards for a network of over 10,000 providers. She has developed recruitment, contracting, and retention strategies for employees, physicians, and ancillary providers.

Ms. Wilmer has a BS in Management from the University of Phoenix and will obtain a BA in Professional Counseling from Liberty University in 2017.

Christopher Randolph, PhD

Chief Scientific Officer

Dr. Randolph has extensive experience in CNS clinical trials work, as an investigator, consultant and creator and supervisor of rater training programs for a large number of Phase II and Phase III multinational studies in Alzheimer’s disease and other neurodegenerative conditions; schizophrenia; stroke; hepatic encephalopathy; and traumatic brain injury.

He also has a strong background and interest in psychometrics and neurocognitive assessment, having worked for over 20 years as a consultant on test development, including the revisions of the Wechsler intelligence and memory scales. He is the author of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a brief neurocognitive battery used widely around the world.

Dr. Randolph is Clinical Professor of Neurology and Director of the Neuropsychology service at Loyola University Medical Center and is board-certified in clinical neuropsychology. He has authored more than 90 peer-reviewed articles on a variety of research interests, including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, traumatic brain injury, sport-related concussion, Tourette’s syndrome, schizophrenia and hepatic encephalopathy.

Dr. Randolph received an undergraduate degree from Vanderbilt University, and MS and PhD degrees from Rutgers University/University of Medicine and Dentistry of New Jersey. He completed an Intramural Training Award fellowship at the Clinical Brain Disorders Branch of the NIMH, and worked as a senior staff fellow in the Experimental Therapeutics Branch of the NINDS.

Michael J. Detke, MD, PhD

Chief Medical Advisor

Dr. Detke is a psychiatrist with more than 20 years of research experience and extensive clinical and drug development expertise. Before joining MedAvante, he served as Executive Director for Neuroscience Medical Research at Lilly Research Laboratories, where he oversaw all CNS assets in early-phase development, including all psychiatric, neurologic and pain indications. Before that, he was Senior Medical Director responsible for Phase III development for Cymbalta (duloxetine HCl) and Phase IV for Prozac (fluoxetine). This role included registration and regulatory commitment trials for Cymbalta, including major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia and chronic pain, as well as pediatric trials.

Dr. Detke teaches and supervises medical students and residents as Clinical Professor of Psychiatry at Indiana University School of Medicine. He graduated summa cum laude with a BA and MS in psychology at Yale University, and received his MA, MD and PhD degrees at the University of Pennsylvania, where he was awarded NIH and NIMH fellowships. He trained in medicine and psychiatry at Harvard Medical School and at the Mt. Auburn, McLean and Massachusetts General Hospitals, and he completed a fellowship in psychopharmacology at Harvard Medical School and McLean Hospital.

Dr. Detke has published more than 60 manuscripts in peer-reviewed journals since 1989. He serves as a reviewer for numerous such journals, and is a member of selective scientific organizations such as the ACNP, ASCP, ISCTM and SOBP.

Janet B. W. Williams, PhD

Senior Vice President, Global Science

Dr. Williams has more than 30 years of clinical research experience in both industry and academia.

Before coming to MedAvante in 2007, she worked for 32 years in academic settings, including as Professor of Clinical Psychiatric Social Work in the Departments of Psychiatry and Neurology at Columbia University College of Physicians and Surgeons, and as Research Scientist and Deputy Chief of the Biometrics Research Department at the New York State Psychiatric Institute. She is now Professor Emerita at Columbia University.

Dr. Williams is well known in the field for her development of psychiatric classifications and instruments to measure psychopathology.

Dr. Williams has a BS in Biology from Tufts University, an MS in marine biology from the University of Massachusetts–Dartmouth, and an MS and PhD in social welfare from the Columbia University School of Social Work. She is the author of more than 240 scholarly publications and serves on the editorial boards of several psychiatric and social work journals. She has received numerous awards for her achievements and contributions in social work and psychiatry.

Scott A. Reines, MD, PhD

Senior Scientist

Dr. Reines has more than 30 years of experience, including broad experience as a senior executive in pharmaceutical R&D.

Before retiring in 2008, he was Senior Vice President for CNS, Pain, and Translational Medicine at Johnson & Johnson Pharmaceutical R&D. During his five years at J&J, Dr. Reines had responsibility for the approvals of Invega for schizophrenia, Reminyl extended release for Alzheimer’s disease, Risperdal Consta for schizophrenia and bipolar disorder, Risperdal for autism, and Topamax for migraine headache and monotherapy in epilepsy. His research groups also led development programs for the analgesic drug tapentadol, the long-acting antipsychotic agent paliperidone palmitate, and other potential treatments for CNS disorders.

Before J&J, Dr. Reines served as Vice President, Clinical Research at Merck, where he was responsible for the development of numerous medically important drugs including therapies for chemotherapy-induced nausea and vomiting, migraine headache, Parkinson’s disease and glaucoma.

Dr. Reines received a BS magna cum laude in chemistry from Cornell University, a PhD in bio/organic chemistry from Columbia University, and an MD from Albert Einstein College of Medicine. He has published in numerous scientific journals including Science, JAMA, NEJM, and the ACNP journal Neuropsychopharmacology. He recently served as the first industry co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and is a member of the Institute of Medicine Forum on Neuroscience. He previously served for five years as a member of the National Drug Abuse Advisory Council and its Bioethics Task Force.

Kenneth A. Kobak

Senior Scientist

Dr. Kobak is a psychologist with more than 30 years of clinical research experience in both industry and university medical settings. Throughout his career, he has focused on clinical assessment, rater training, rating scale development and clinical trials methodology.

Prior to MedAvante, Dr. Kobak founded the consultancy Research Training Associates, where he developed new methodologies for training and calibrating raters in clinical trials using digital technologies.

At the University of Wisconsin Medical School and Healthcare Technology Systems, Dr. Kobak managed a clinical trials unit and pioneered the use of computer-administered rating scales in clinical trials. He authored computer-administered versions of several clinician-administered rating scales, including depression and anxiety scales that are widely used today, and a computer-administered version of the PRIME-MD, a diagnostic interview that was published in JAMA.

Dr. Kobak received his BA, MSSW, and PhD from the University of Wisconsin-Madison. He is co-author of the Rater Applied Performance Scale (RAPS), which is widely used to evaluate raters’ applied clinical skills in administering symptom rating scales, and is co-author with Dr. Janet Williams of the SIGMA, a structured interview guide for the Montgomery-Asberg Depression Rating Scale. Dr. Kobak received several NIMH grants to develop and study rater training methodology for depression, schizophrenia, and autism. He received a New Investigator Award from NIMH in 1996, and is a core member of the Depression Rating Scale Standardization Team (DRSST).

Jason Brandt

Senior Scientist

Dr. Brandt is a Professor of Psychiatry and Behavioral Sciences, Professor of Neurology and Director of the Division of Medical Psychology at the Johns Hopkins University School of Medicine. He is also Director of the Cortical Function Laboratory at the Johns Hopkins Hospital.

Dr. Brandt’s research focuses on the neuropsychology of memory and other cognitive disorders as they appear in Alzheimer’s disease, Huntington’s disease, and other dementia syndromes. He has also investigated the cognitive changes associated with epilepsy and its treatments, the psychological consequences of genetic testing for neuropsychiatric disorders, and improved methods for neuropsychological assessment. He published more than 300 journal articles and book chapters on these and related topics. Dr. Brandt developed widely used neuropsychological tests including the Hopkins Verbal Learning Test – Revised and the Telephone Interview for Cognitive Status.

Dr. Brandt served as President of both the Society for Clinical Neuropsychology (APA, Division 40) and the International Neuropsychological Society. He was named a “Hero of Medicine” by TIME magazine in 1997 and received the Career Achievement Award from the International Neuropsychological Society in 2015.

Selam Negash

Senior Scientist

Dr. Negash serves as the scientific lead bridging research and operations to ensure MedAvante clinical trial services are implemented successfully from a scientific and service delivery perspective. Prior to joining MedAvante, she was a Research Associate at the Penn Memory Center, a National Institute on Aging-designated Alzheimer’s Disease Center (ADC). Her work has focused on investigating factors associated with successful cognitive aging, including lifestyle factors such as cognitive activity, and on developing interventions that enhance cognitive fitness in older adults. She also studies successful cognitive aging in minority populations, particularly African-Americans. Her other area of work focuses on examining implicit and explicit learning and memory systems in healthy aging and in mild cognitive impairment.

She received her doctoral training in neuroscience from Georgetown University and completed her postdoctoral training in the Alzheimer’s Disease Research Center at Mayo Clinic Rochester, where she also earned the Master of Science degree in the Clinical Research Program.

John M. Kane, MD

Chief Scientific Advisor

Dr. Kane is Senior Vice President for Behavioral Health Services at North Shore-Long Island Jewish Health System in New Hyde Park, New York. He is Chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Additionally, he is Professor and Chairman of Psychiatry at The Hofstra North Shore-LIJ School of Medicine. Dr. Kane earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society. Dr. Kane has been the principal investigator for research projects focusing on schizophrenia, psychobiolgy and treatment, recovery, and improving quality and cost of care. He is the author of over 400 peer-reviewed papers and serves on the editorial boards of numerous journals.

Michael Ropacki, PhD

Vice President, Research and Development

Dr. Ropacki is an accomplished clinical researcher with experience in all phases of clinical development. In his current role as Vice President, Research and Development, he serves as the therapeutic leader for Psychiatry and new therapeutic areas, and oversees MedAvante’s scientific research including presentations and publications.

Dr. Ropacki worked for Janssen Research & Development (Johnson & Johnson) for 13 years, and last served as a Director, Clinical Research Neuroscience, Research and Development. In this capacity he was the Clinical Leader the Cognitive Health in Aging Registry: Investigational, Observational and Trial studies in dementia research – Prospective Readiness Cohort (CHARIOT-PRO) program, and was responsible for the development and execution of other clinical programs within the neuroscience therapeutic area.

Dr. Ropacki serves as Co-Chair of a Scientific Advisory Group for the Innovative Medicines Initiative-European Prevention of Alzheimer’s Dementia (IMI-EPAD) program, and is a National Institute of Health (NIH) advisor to the National Institute on Aging (NIA), National Institute of Neurologic Disorders and Stroke (NINDS) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). He is a member of the Critical Path Institute’s (C-Path) Coalition Against Major Disease (CAMD) digital Drug Development Tool (dDDT) Team. Previously, he was Co-Chair of the CAMD Preclinical Cognitive Outcome Assessment (COA) team working with the Food and Drug Administration’s Drug Development Tool, COA Qualification Program. Dr. Ropacki authored or co-authored of dozens of published manuscripts and abstracts, and was an Assistant Clinical Professor of Neurology at the Loma Linda University School of Medicine.

Dr. Ropacki holds a bachelor degree Summa Cum Laude from University of Arizona, a master degree and doctorate from Texas Tech University, completed his internship/residency at University of Oklahoma Health Sciences Center in Psychiatry, and two post-doctoral fellowships at Brown University School of Medicine and UCLA School of Medicine in Psychiatry.

Sue Vallow, RPh MBA MA

Vice President, Patient eSolutions

Sue Vallow is a patient-reported outcomes (PRO) scientist with more than 20 years of experience developing and implementing patient-focused outcomes strategies and capabilities in numerous therapeutic areas with a specialty in CNS trials. She leads the expansion of MedAvante’s Virgil Investigative Study Platform into trials that rely on PROs as key endpoint measures.

Prior to joining MedAvante, she was Senior Director and Head of Patient Focused Outcomes at GSK, where she built and managed the team responsible for patient outcomes strategies, as well as electronic patient reported outcomes (ePRO) implementation in clinical trials. Prior to GSK, she worked at Janssen in a leading role for PRO implementation in neuroscience.

Active in industry-wide patient-focused initiatives to forward the science of patient input in drug development, she served as co-chair of the ePRO subcommittee of the Critical-Path Institute’s Patient Reported Outcomes Consortium, a member of PhRMA’s PRO working group, and a leader in the TransCelerate Patient Experience & Technology initiative. She is a co-author of more than 20 peer-reviewed papers and more than 70 research posters and presentations.

Ms. Vallow earned a BS degree in pharmacy and MA in economics from Temple University and an MBA Villanova University.

Ian Neilson

Senior Vice President, Global IT

Ian C. Neilson leads MedAvante’s worldwide IT team, including software and platform development and support, network operations and data management. He has more than 30 years of experience in eClinical development, including 19 years as a key senior IT executive at Covance, now a division of LabCorp Holdings.

Prior to joining MedAvante, he was Vice President, Technology and Innovation within the Clinical Development Services division of Covance. Neilson was a member of the Clinical Development executive leadership team, developing the IT roadmap for long range strategic plans, and he oversaw a team of 100 IT professionals responsible for successfully delivering a multi-year, multi-million dollar process and technology transformation program. Neilson previously led IT Architecture and Compliance for Covance with responsibility for establishing and implementing IT standards, security, and quality and compliance processes across the company. His professional accomplishments at Covance included serving as IT leader on the Diamond II eClinical Initiative, deploying key initiatives such as a state-of-the art CTMS, eTMF, SAS Data Analysis and Reporting, Bedside Data Capture, and Drug Safety process optimization.

Mr. Neilson holds a BA from Heriot-Watt University, Edinburgh.

Scientific Advisory Boards

Recognized experts and key opinion leaders in various fields play a vital role in shaping and refining MedAvante’s solutions. Our Scientific Advisory Boards meet regularly to review research progress and recommend improvements for our methods and procedures.

PSYCHIATRY

Twelve board members from leading universities and research institutions provide counsel and guidance to MedAvante on initiatives relating to mood, anxiety, schizophrenia, and other psychiatric disorders.

MedAvante’s Psychiatric Advisory Board is co-chaired by John M. Kane, MD, Chairman of the Department of Psychiatry at the Zucker Hillside Hospital and Professor of Psychiatry, Neurology and Neuroscience at the Albert Einstein College of Medicine, where he is the Dr. E. Richard Feinberg Chair in Schizophrenia Research.

 

ALZHEIMER’S DISEASE: US and Europe

Eight distinguished experts from leading American and European institutions engaged in neurocognition research guide the development of MedAvante’s signal detection solutions in Alzheimer’s disease, Parkinson’s disease and related neurodegenerative disorders.

MedAvante’s US/European Alzheimer’s advisory board is co-chaired by Jeffrey Cummings, MD, the Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada.

ALZHEIMER’S DISEASE: Japan

Our second Alzheimer’s advisory board guides the application of MedAvante’s clinical trial solutions in Japan. Eleven top leaders from major Japanese universities and research institutions provide their expertise to enhance MedAvante’s ability to collect high-quality research data with less error and greater signal detection.

MedAvante’s Japanese Alzheimer’s advisory board is co-chaired by Masatoshi Takeda, MD, PhD, Chairman and Professor of Psychiatry at the Osaka University Graduate School of Medicine.

geo-abstract-green copy

PRINCIPAL INVESTIGATORS

MedAvante’s dedicated Principal Investigator advisory board includes twelve research leaders from major investigative sites to ensure that our services are highly attuned to the needs of clinical trial sites and investigators. Input from this advisory board was instrumental in the development of the Virgil Investigative Study Platform.

Careers

MedAvante is always seeking talented
people to join our world-class team.

At MedAvante, we look for colleagues who combine talent with a powerful desire to change healthcare for the better and ensure that effective therapies make it to the patients who need them. This is the mission uniting the clinicians, scientists, technologists, and operations experts whose mix of energy, inventiveness, and skill fuels MedAvante’s relentless quest to improve clinical trials.

We welcome new colleagues who share the commitment to innovation that has won us blue-chip private equity backing from Goldman Sachs, Trevi Health, and Essex Woodlands.

We look for:

  • A commitment to making a difference
  • A desire to work with and learn from talented colleagues
  • The ability to be both self-motivated and a team player
  • Intellectual curiosity
  • The passion to build technological tools to conduct more efficient and effective clinical trials
  • The desire to question the status quo and learn from mistakes
  • Comfort with thinking logically
  • A drive to improve and achieve
  • People who are compassionate, visionary, articulate, ambitious, fun, precise, sympathetic, driven, curious, energetic, inspiring and trustworthy

Got what it takes?

See jobs

Peter

Client Services

Spain

What do you do at MedAvante?
As a member of the Business Development team, I am responsible for overseeing the creation of our responses to requests for information and proposals from drug development sponsors planning clinical trials. I also serve as a subject matter expert on clinical and technical aspects of our service solutions.

Why did you decide to work at MedAvante?
When MedAvante was looking to expand into the Alzheimer’s area with a focus on improving data quality, I found a great match with my background as Clinical Neuropsychologist and previous experience in rater training and quality control.

What do you like best about your job?
MedAvante lacks the layers of hierarchy that can kill good ideas or contributions from different departments, and our entire team is determined to stay on the forefront of signal detection and clinical trial technology.

What are your colleagues like?
Hard working, open and approachable.
They like to be challenged, and they constantly push the limits of their comfort zone to ensure that quality of service is the first thing any customer remembers. And we are each other’s safety net when push comes to shove.

What impact has working at MedAvante had on you?
I have been able to apply my clinical and operational background to a more business driven area, and I am able to help shape the image of MedAvante in the customer’s mind.

Lisa

Clinical Trial Services

USA/NJ

What do you do at MedAvante?
My job is to perform live clinical psychiatric interviews by phone and video conferencing with study subjects participating in clinical trials. I also review documents and recordings of neuropsychological and psychiatric assessments conducted by other clinicians to provide feedback on scoring and administration.

Why did you decide to work at MedAvante?
I found in MedAvante a great place to use my behavioral health experience in a clinical trials setting, as well as a perfect fit for my years of face-to-face counseling, neuropsychological assessments, and phone work at an employee assistance program provider.

What do you like best about your job?
I like the excellent training, as well as the opportunity to work with a dedicated group of professionals. I also greatly appreciate my manager’s skillset and guidance.

What are your colleagues like?
I have worked a number of places in my career before MedAvante but I never met a more caring and dedicated group of employees as I have here. While I work in the office, I feel just as connected to my peers who work remotely.

What impact has working at MedAvante had on you?
The learning at MedAvante for me started on day one, and has never stopped. As the company grows, so does my ability to gain further skills as a clinician and professional in different research areas.

Gloria

Project Management

USA/NJ

What do you do at MedAvante?
I am a member of a global team that’s the primary point of contact for clinical trial sponsors as well as principal investigators and study coordinators. I administer the adjudication process for large global studies by tracking cases, contacting sites for needed information, and assembling and storing the required documentation.

Why did you decide to work at MedAvante?
I come from the medical field, having graduated as a Medical Doctor in Dominican Republic. In MedAvante I’ve found a company is multicultural and gives me the opportunity to interact with other colleagues around the world.

What do you like best about your job?
I really love the flexibility that makes my work very convenient for me and my family. I also like the way our multicultural team all treats each other with respect and I enjoy working with colleagues from around the world.

What are your colleagues like?
In our department we are very diverse in culture, beliefs and opinions, but there is something common in all of us and that is the respect and the compassion we all have. My colleagues really care about each other and are willing to help and support.

What impact has working at MedAvante had on you?
Working here has helped me take personal responsibility for learning and development, and increased my understanding that there is a lot more to do in the pharma world.

Myriam

Project Management

France

What do you do at MedAvante?
I interact with people from all over the world in my job, exchanging information, optimizing various processes, and, most importantly, providing high quality technical support and customer service to our clinical trial sites. The nature of our work is such that I am constantly learning new things, and I must steadily exercise and develop my skills.

Why did you decide to work at MedAvante?
When I first came across the MedAvante job opening, I knew the skills I had acquired during my career up to that point would make me a strong candidate. On the other hand, medical research was a completely new field for me. Therefore, the job was both a good fit and a big challenge for me. I had to apply.

What do you like best about your job?
Every day is interesting and challenging, it might be a bit hard, but it is never boring. I love being trusted to oversee and carry out projects with my co-workers. It makes me feel part of a team and boosts my confidence.

What are your colleagues like?
My colleagues are hardworking, bright and talented people. We work as a team. Each one of us tries our best to produce a collective result that is optimal for our company and for our clients. My co-workers have my back, as I have theirs. Therefore, a strong bond has developed between us.

What impact has working at MedAvante had on you?
I have acquired more skills in four years at MedAvante than in my entire previous career. My problem solving skills have improved and I have gained experience in productively interacting with people of very different professional or cultural backgrounds.

Sumanth

Software Development

USA/NJ

What do you do at MedAvante?
I manage software development and delivery for our Virgil platform: intuitively interactive digital forms for clinician assessments and patient reports. I keep a close eye on what’s going well and what is not to ensure our immediate development roadmap is clear, and I work with senior management on strategic long term product planning.

Why did you decide to work at MedAvante?
MedAvante looked attractive to me first and foremost due to the people I met when I interviewed. They are highly intelligent, excited by the opportunity to develop new solutions, and committed to growing the company and their careers.

What do you like best about your job?
I like that I am achieving all that I had hoped for when I was still thinking about joining the company – working with highly intelligent colleagues and finding opportunities to develop new solutions.

What are your colleagues like?
They are super smart, cooperative and driven to excel at what they are doing. I think anyone who has a solid command of his or her knowledge domain and is respectful towards others can succeed here.

What impact has working at MedAvante had on you?
I am inspired by feedback from customers and especially when they validate our ideas by accepting the solutions we build for them. I have become a more confident leader and a better team player.

Douglas

Clinical Trial Services

USA/Ohio

What do you do at MedAvante?
I have daily contact with clinical trial sites and sponsors of studies around the world, attending teleconferences with each of the study teams and training other clinicians both internally and at sites. I also track statistical data on my studies and resolve discrepancies and other clinical queries.

Why did you decide to work at MedAvante?
A graduate school classmate who worked for MedAvante told me about the company’s goal of improving clinical studies and I was excited to become a part of it. Everyone here has been incredibly supportive and collaborative.

What do you like best about your job?
I like having the opportunity to work with so many different people in so many different countries, not only our staff but also training people working on trials supported by our technology and services. I really appreciate the opportunity to travel, collaborating with and presenting to scientific leaders.

What are your colleagues like?
My colleagues are helpful and hardworking, and also very supportive. We truly have a team mentality and we all work to assist one another and elevate each other in any way possible. They are all very knowledgeable and experienced and are able to guide sites and sponsors when needed.

What impact has working at MedAvante had on you?
My job has allowed me to work with scientific experts and learn about new indications and scales. I have also learned much about study design and how to work within the different agencies and sites internationally.

Nick

Project Management

Japan

What do you do at MedAvante?
I am a senior project manager in Asia Pacific region, which means that I mainly take care of day-to-day project status and working very closely with the study sites. I am responsible for communicating with global study sponsors and an important part or my role is to confirm that our procedures match local culture.

Why did you decide to work at MedAvante?
The freedom of working style and an opportunity to help make the MedAvante reputation as a good vendor provider between the Japan sites and sponsors, an achievement that took me and our team many years and lot of time to achieve.

What do you like best about your job?
You are free to decide how you manage your own project, task, time, working style and which you can’t find in other companies.

What are your colleagues like?
We are a dream team. My colleagues like to help and support each other like a family and they are a part of my soul in my job.

What impact has working at MedAvante had on you?
Because MedAvante is a professional company specifically focused in the CNS therapeutic area, I have had the opportunity to become a CNS professional myself, unlike my past work in a CRO when I needed to work in many areas without that identity.

Carlos

IT

USA/NJ

What do you do at MedAvante?
I am responsible for global infrastructure, support, and security so my work can be very challenging but also very rewarding. Some days it’s evaluating the right technology and solution to drive our company forward, others days are spent solving specific problems. Our goal is to support every customer – internal or external – with a smile while making infrastructure as seamless as possible.

Why did you decide to work at MedAvante?
The passion and drive that MedAvante has as a company is what drove me to join. During my interview I was really impressed with how perfectly the company aligned with what I was looking for.

What do you like best about your job?
I love technology, and I believe we have the opportunity to be on the cutting edge and continue investing in our future. We are a technology company that is really focused on making this world a better place by dramatically improving clinical trials.

What are your colleagues like?
We are a highly diverse company with a mixture of many cultures. I really like learning about people and their passion, and I feel lucky to work with some really great people who are passionate about what they do and driven to get results.

What impact has working at MedAvante had on you?
I would say that this opportunity has given me the ability to work with many large pharma companies, giving me a really great perspective of how much of a difference our products can make to clinical trials.

Ron

Clinical Trial Services

Netherlands

What do you do at MedAvante?
The main theme in my scientific career has been memory research and the enhancement effects of neurotrophic drugs like neuropeptides in patients with memory disturbances, and dementia. Since retiring from my university position as head of the Clinical Neuropsychology department, I have been working as a MedAvante trainer and clinician.

Why did you decide to work at MedAvante?
I decided to accept the invitation to work for MedAvante because I knew they share my belief that the lack of solid methodology, structured assessments and knowledge about statistical analyses has often biased the outcome of psychiatric and cognitive studies.

What do you like best about your job?
The company is focused on solid methodology, standardized training and calibration of clinicians and trainers. I value the opportunity to pass on my experience to people from different background and cultures.

What are your colleagues like?
Professional, enthusiastic, hardworking people. They try to improve and stimulate each other, and MedAvante indeed works hard to create an atmosphere of “belonging to the MedAvante family.”

What impact has working at MedAvante had on you?
I have been inspired by the opportunity to work with people from different background and cultures.

Desiree

Project Management

USA/NJ

What do you do at MedAvante?
I manage Project Services including Customer Support, Technical Support and Fulfillment. My day consists of problem solving, revamping processes and motivating a team of hardworking individuals. My goal each day is to leave the office knowing that I accomplished something within my department or added a thought that will inspire innovation.

Why did you decide to work at MedAvante?
I saw an opportunity to work with a growing company at the forefront of innovation in clinical research. I believe in MedAvante’s values and mission, and felt that I had a unique perspective to contribute to the company’s growth.

What do you like best about your job?
I like that my opinion counts and that I am able to contribute to products and processes that can revolutionize this industry. I am not a number here but a part of a family. Every day I get to add to the forward progress of an ever evolving industry.

What are your colleagues like?
My colleagues are my family, the most compassionate, ambitious, committed group of people. I find it inspiring to work with people who are passionate about what they do, consistently dedicating their time and energy to help bring effective therapies to people who need them.

What impact has working at MedAvante had on you?
Working at Medavante allows me to use my creative brain to engage and inspire people and I know my contribution means something. I can look at a product and say “Wow, I did that”. That’s allowing me to grow more confident as a manager with a strategic vision for this ever evolving industry.

Application Process

Please apply online with your CV and cover letter in English. Candidates for clinical positions may be asked to complete a Clinical Experience Questionnaire. After the CV screening, selected candidates will be contacted in order to schedule phone or Skype interviews.

We value your interest in MedAvante and try to review all submissions in a timely manner. MedAvante strives to continuously improve our application process and candidate experience. Therefore, we welcome your feedback on Glassdoor or by e-mail to hr@medavante.com

Who we are

About Us

MedAvante, founded in 2002, is a leading global clinical data services company. Our offerings include the tablet-based Virgil Investigative Study Platform and scientific risk-reduction services – including Rater Qualification & Training, Central Review and Central Ratings – to support clinical trials of treatments for central nervous system (CNS) and other disorders.

MedAvante is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age or veteran status.

See jobs

Our Locations

The MedAvante corporate headquarters is located in Hamilton NJ, which is easily accessible via NJ Transit and within walking distance to the Hamilton train station.

Our Munich office was established in 2011 and is functioning as a hub office for providing services in Europe and Asia-Pacific. The office is located within the MTZ technology centre.

In addition MedAvante employs remote, home based employees and consultants in Bangladesh, Bulgaria, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, South Korea, Spain, Turkey, United Kingdom, Ukraine and the United States.

What we offer

MedAvante offers a competitive salary & comprehensive benefits package to eligible employees, including (but not limited to):

In the US:

In all other countries:

See jobs

MedAvante’s Timeline

2005

MedAvante breaks new ground with its Central Ratings methodology.

2009

Building on its Central Ratings expertise, MedAvante pioneers eSource.

2010

MedAvante expands to providing service in global trials.

First MedAvante-generated eSource data accepted by FDA as part of a successful drug approval.

2013

FDA issues guidance encouraging the industry adoption of eSource solutions – which MedAvante has already been developing for five years.

2014

MedAvante launches the Virgil Investigative Study Platform.

2015

Milestone: Three and a half million pages of paper captured digitally by Virgil — without losing a single data point. If stacked, the pages would exceed the height of The Empire State Building.

2016

Virgil continues to evolve with regular platform updates driven by site-based research and feedback.

MedAvante provides global services with native-language clinicians in over 40 countries.

We’re committed to providing the tools for smarter, faster clinical trials. With Virgil, the future looks even brighter.

MedAvante Worldwide